Experienced in Splenectomy

Dr. Mansoor Saleh

Hematology
Office
1824 6th St S, 
Birmingham, AL 
Experienced in Splenectomy
Office
1824 6th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mansoor Saleh is a Hematologist in Birmingham, Alabama. Dr. Saleh is rated as an Experienced provider by MediFind in Splenectomy. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Blood Clots, and Splenectomy.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
1824 6th St S, Birmingham, AL 35205
Other Locations
Georgia Cancer Specialists I PC
1835 Savoy Dr Ste 300, Atlanta, GA 30341

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

72 Total Publications

Clinical Manifestations.
Clinical Manifestations.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 25, 2025
Similar Doctors
Experienced in Splenectomy
Dr. Radhika Gangaraju
Hematology
Experienced in Splenectomy
Dr. Radhika Gangaraju
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (141.8 miles away)
205-934-3411
Languages Spoken:
English
See accepted insurances

Radhika Gangaraju is a Hematologist in Birmingham, Alabama. Dr. Gangaraju is rated as a Distinguished provider by MediFind in Splenectomy. Her top areas of expertise are Purpura, Thrombocytopenia, Venous Thromboembolism (VTE), Bone Marrow Transplant, and Splenectomy.

Experienced in Splenectomy
Dr. Lee Hilliard
Hematology | Oncology
Experienced in Splenectomy
Dr. Lee Hilliard
Hematology | Oncology

Children's Of Alabama

1600 7th Ave S, 
Birmingham, AL 
 (142.1 miles away)
205-638-9285
Languages Spoken:
English
See accepted insurances

Lee Hilliard is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Hilliard is rated as an Advanced provider by MediFind in Splenectomy. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy.

Experienced in Splenectomy
Dr. Giri Smith
Hematology
Experienced in Splenectomy
Dr. Giri Smith
Hematology

Whatley Health Services Inc

809 University Blvd E, 
Tuscaloosa, AL 
 (187.3 miles away)
205-759-7800
Languages Spoken:
English
See accepted insurances

Giri Smith is a Hematologist in Tuscaloosa, Alabama. Dr. Smith is rated as a Distinguished provider by MediFind in Splenectomy. His top areas of expertise are Multiple Myeloma, Essential Thrombocythemia, Acute Myeloid Leukemia (AML), Splenectomy, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saleh's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile